{
    "Title": "Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection",
    "URL": "https://doi.org/10.1371/journal.pntd.0007890",
    "Published": "November 21, 2019",
    "Subject_Areas": [
        "Ebola virus",
        "Blood plasma",
        "HeLa cells",
        "Cytokines",
        "Pharmacokinetics",
        "Mouse models",
        "Chemokines",
        "Euthanasia"
    ],
    "Authors": {
        "Thomas R. Lane": [
            "Collaborations Pharmaceuticals, Inc., Raleigh, NC, United States of America"
        ],
        "Christopher Massey": [
            "Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States of America"
        ],
        "Jason E. Comer": [
            "Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States of America",
            "Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX, United States of America",
            "Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, United States of America"
        ],
        "Manu Anantpadma": [
            "Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX, United States of America"
        ],
        "Joel S. Freundlich": [
            "Departments of Pharmacology, Physiology, and Neuroscience & Medicine, Center for Emerging and Reemerging Pathogens, Rutgers University\u2013New Jersey Medical School, NJ, United States of America"
        ],
        "Robert A. Davey": [
            "Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX, United States of America"
        ],
        "Peter B. Madrid": [
            "SRI International, Menlo Park, CA, United States of America"
        ],
        "Sean Ekins": [
            "Collaborations Pharmaceuticals, Inc., Raleigh, NC, United States of America"
        ]
    }
}